Markets:

Overview

News

Currencies

International

Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

80.78 -1.00 (-1.22%)

Streaming Delayed Price Updated: 12:35 PM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1

July 27, 2026

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

July 26, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

July 24, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...

Via StockStory

2 Reasons to Watch ANIP and 1 to Stay Cautious

July 24, 2026

Since January 2026, ANI Pharmaceuticals has been in a holding pattern, posting a small loss of 3.5% while floating around $78.49. The stock also fell short o...

Via StockStory

ANI Pharmaceuticals (NASDAQ:ANIP) Crushes Q1 Estimates, Raises Full-Year Guidance ↗

May 08, 2026

Via Chartmill

2 Small-Cap Stocks Worth Investigating and 1 We Brush Off

July 21, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run ↗

July 12, 2026

Carey exercised vested options under a pre-established Rule 10b5-1 trading plan adopted in March, retaining 177,543 directly held shares.

Via The Motley Fool

Topics Economy Regulatory Compliance

2 Value Stocks for Long-Term Investors and 1 We Avoid

July 10, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Via StockStory

ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge ↗

July 09, 2026

This specialty pharma company, known for its branded and generic drug portfolio, just reported a notable insider sale in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

July 06, 2026

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 of Wall Street’s Favorite Stocks to Target This Week

July 06, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

2 Cash-Producing Stocks to Research Further and 1 Facing Challenges

June 09, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Ani (ANIP) Q1 2026 Earnings Call Transcript ↗

June 01, 2026

Ani (ANIP) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

2 Growth Stocks with Explosive Upside and 1 We Avoid

May 29, 2026

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Via StockStory

Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks

May 18, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds

May 14, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million ↗

May 11, 2026

ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.

Via The Motley Fool

ANI Pharmaceuticals Q1 Earnings Call Highlights ↗

May 08, 2026

ANI Pharmaceuticals (NASDAQ:ANIP) reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease...

Via MarketBeat

Topics Earnings Intellectual Property

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q1 CY2026, Stock Soars

May 08, 2026

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q1 CY2026, with sales up 20.5% year on year to $...

Via StockStory

ANI Pharmaceuticals (ANIP) Q1 Earnings: What To Expect

May 06, 2026

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before market open. Here’s what you need to know. A...

Via StockStory

Topics Artificial Intelligence

Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks

April 26, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Winners And Losers Of Q4: Elanco (NYSE:ELAN) Vs The Rest Of The Pharmaceuticals Stocks

April 22, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Cash-Producing Stock with Promising Prospects and 2 Facing Challenges

April 14, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

Topics Economy

1 Small-Cap Stock for Long-Term Investors and 2 We Turn Down

April 13, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know

April 07, 2026

What Happened? A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage ...

Via StockStory

3 Russell 2000 Stocks We Steer Clear Of

March 30, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...

Via StockStory

ANI Pharma Insider Sells 4,772 Shares as Revenue Hits $883 Million in 2025 ↗

March 27, 2026

Specializing in branded and generic pharmaceuticals, this sector player reported a notable insider sale amid a stable transaction pattern.

Via The Motley Fool

Topics Regulatory Compliance

3 Reasons ANIP is Risky and 1 Stock to Buy Instead

March 24, 2026

What a brutal six months it’s been for ANI Pharmaceuticals. The stock has dropped 22.2% and now trades at $73.90, rattling many shareholders. This may have i...

Via StockStory

Topics Supply Chain

2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Question

March 20, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

March 11, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.